Table 1.
Demographic and Clinical Characteristics of Patients with and without CNS Neurotoxicity
| Neurotoxicity (n = 34) | Non-Neurotoxicity (n = 131) | Total (N = 165) n% | |
|---|---|---|---|
| Demographics | |||
| Sex, female (male) | 5 (29) | 33 (98) | 38 (127) |
| Age(years), median (IQR) | 56 (45, 64) | 53 (44.5, 65) | 54 (45, 65) |
| Weight(kg), median (IQR) | 63 (59, 69) | 63 (56, 70) | 63 (56, 70) |
| Underlying condition | |||
| Viral hepatitis | 19 (55.9) | 76 (58.0) | 95 (57.6) |
| Liver cirrhosis | 14 (41.2) | 47 (35.9) | 61 (37.0) |
| Liver failure | 14 (41.2) | 37 (28.2) | 51 (30.9) |
| Hypertension | 2 (5.9) | 17 (13.0) | 19 (11.5) |
| Others | 8 (23.5) | 33 (25.2) | 41 (24.8) |
| Route of administration | |||
| Intravenous | 10 (29.4) | 51 (38.9) | 61 (37) |
| Oral | 24 (70.6) | 80 (61.1) | 104 (63) |
| Site of infection | |||
| Lung | 11 (32.4) | 57 (43.5) | 68 (41.2) |
| Abdominal cavity | 3 (8.8) | 4 (3.1) | 7 (4.2) |
| Intestinal tract | 1 (3) | 3 (2.3) | 4 (2.4) |
| Others | 2 (5.9) | 5 (3.8) | 7 (4.2) |
| Number of concomitant use of neurotoxic drugs | |||
| Overall | 31 (91.2) | 110 (84.0) | 141 (85.5) |
| Fluoroquinolone | 11 (32.4) | 30 (23.0) | 41 (24.8) |
| Cephalosporins | 4 (11.8) | 15 (11.5) | 19 (11.5) |
| Carbapenems | 18 (52.9) | 61 (46.6) | 79 (47.9) |
| Linezolid | 9 (26.5) | 23 (17.6) | 32 (19.4) |
| Others | 15 (44.1) | 73 (55.7) | 88 (53.3) |
| Central nervous system toxicity symptoms | |||
| Visual impairment | |||
| Blurred vision | 4 (11.8) | - | 4 (2.4) |
| Othersa | 4 (11.8) | - | 4 (2.4) |
| Nervous system disorder | |||
| Hallucinations | 9 (26.5) | - | 9 (5.5) |
| Altered mental state | 4 (11.8) | - | 4 (2.4) |
| Dizzy | 3 (8.8) | - | 3 (1.8) |
| Hepatic encephalopathy | 2 (5.9) | - | 2 (1.2) |
| Othersb | 8 (23.5) | - | 8 (4.8) |
| Metabolizer phenotype | |||
| UM | 0 | 1 (7.6) | 1 (6.1) |
| EM | 12 (35.3) | 35 (26.7) | 47 (28.5) |
| IM | 9 (26.5) | 43 (32.8) | 52 (31.5) |
| PM | 5 (14.7) | 17 (13.0) | 22 (13.3) |
Notes: aOthers include dazzled (n = 2), altered color perception (n = 2). bOthers include tremor (n = 2), drowsiness (n = 2), confusion (n = 1), paresthesia (n = 1), tinnitus (n = 2).
Abbreviations: IQR, interquartile range; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.